Implant offers ray of hope for Alzheimer's patients

Shunt that drains fluid may reduce disease progress

Life After 50

January 12, 2003|By Jane E. Allen | By Jane E. Allen,Special to the Sun

Alzheimer's research has yet to yield many useful therapies, even as the demand for treatments grows -- U.S. cases are expected to increase from 4 million to as many as 16 million by the middle of this century. A promising vaccine produced brain inflammation; medications that help patients function better during the early and moderate stages eventually lose ground to the incurable disease; and newer compounds to treat and prevent it remain years from reaching pharmacies.

So it's not surprising that scores of people with Alz-heimer's are signing up to have shunts implanted in their brains, an invasive approach that has become one of the few bright spots in Alzheimer's research.

Dr. Gerald Silverberg, a neurosurgeon at California's Stanford University School of Medicine, reported recently that experimental shunts had slowed disease progression in a small group of patients. In that pilot study, published in Neurology, he and his colleagues compared 12 patients who had mild to moderate Alzheimer's who underwent shunt implantation with 11 Alzheimer's patients who received traditional care. After a year of monitoring and evaluation, the surgical patients remained stable; the comparison patients declined.

The shunts are designed to slowly drain away toxins from fluid bathing the brain and spinal cord. The initial study not only found the technique essentially safe -- no participants died or suffered permanent complications -- it also found lower levels of toxic protein fragments in shunted patients' brain fluid.

Although Silverberg hasn't formally monitored those he operated on three years ago, he said their families report they have not deteriorated. "They are still living at home, still functioning, still caring for themselves and don't require nursing home placement," he said. Such success is notable, given the disease's usual progression. Silverberg formed a private company with three colleagues to produce and further test the shunt. An expanded trial, at 25 sites nationwide, aims to establish whether the device's apparent early success holds up. If it does, Silverberg said, "Ours will be the first therapy that appears to alter the course of the disease."

The early promise was enough for scores of patients desperate to slow or halt Alzheimer's inexorable decline.

Among them is John F. Harvey, an 83-year-old retired Air Force colonel diagnosed about 4 1/2 years ago. He underwent implantation of an experimental shunt in July at Southwest Texas Medical Center in San Antonio.

His wife, Lilas, said the two agreed to his participation because his physical health is excellent and his disease has been fairly stable for about three years; they're hoping to keep it that way. "The most important thing was that if he could be stabilized, then he would be able to stay home," Lilas Harvey said.

Because he's part of a randomized, placebo-controlled trial, Harvey doesn't know whether his shunt is working or whether it's one of the comparison shunts that will remain closed for the first nine months of the experiment. After that, closed shunts will be opened so all participants can receive potential benefits.

The idea behind the shunt, Silverberg said, stemmed from observations that patients with hydrocephalus -- water on the brain -- had a high incidence of Alzheimer's. Both conditions involve decreased turnover of cerebrospinal fluid. Silverberg says that because their fluid is more stagnant, Alzheimer's patients have a hard time clearing out their excess of amyloid-beta protein fragments, called peptides. As a result, the peptides glom together and attach to brain cells, causing inflammation and damage.

By speeding up the elimination of fluid containing these peptides and allowing fresh fluid to take its place, the Stanford researchers hypothesized, patients might do better. They modified existing shunts -- narrow catheters commonly used in hydrocephalus -- with a low-flow valve that keeps fluid flowing at a constant rate, regardless of changing pressure inside the skull.

The rationale behind the shunt procedure is valid, and a larger trial is warranted, said Greg M. Cole, associate director of the UCLA Alzheimer's Disease Research Center at the University of California at Los Angeles.

Dr. Zaven Khachaturian, a medical and scientific adviser in Washington to the Alzheimer's Association, said that, although surgery seems "a bit drastic," the work might lead to less invasive ways of addressing the problem.

Jane E. Allen is a reporter for the Los Angeles Times, a Tribune Publishing newspaper.

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.